Esperion Therapeutics (ESPR) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Needham & Company Upgrades Esperion Therapeutics (ESPR) to Strong Buy; Shares Will Rebound
August 10, 2015 7:08 AM EDTNeedham & Company upgraded Esperion Therapeutics (NASDAQ: ESPR) from Buy to Strong Buy with a price target of $130.00.
Analyst Chan Messer commented, "ESPR shares have recently pulled back over regulatory concerns. Some investors feel that an evolution of thinking at the FDA about... More
UBS Reiterates Buy on Esperion Therapeutics (ESPR) Ahead of FDA Meeting; Sees Meaningful Upside
August 7, 2015 10:46 AM EDTUBS analyst Andrew Peters reiterated his Buy rating and $140 price target on Esperion Therapeutics (NASDAQ: ESPR), which suggests 152% upside from yesterday's close. Comments following in-line Q2 results and comments from the conference call which add color ahead of the FDA meeting.
"2Q15 financial results were in line with expectations, with management focusing the conf. call on addressing recent investor questions on ETC-1002 and regulatory risk," Peters commented. " With the recent pull-back in... More
Chardan Capital Trims PT on Esperion (ESPR) Following Q2 Results, TAK-475 Failure Concerning for ETC-1002
August 7, 2015 8:30 AM EDTChardan Capital affirms its Sell rating on Esperion (Nasdaq: ESPR) and cuts its price target from $45 to $40 following Q2 results.
Analyst Gbola Amusa commented, Esperion reported 2Q basic and diluted EPS of -$0.55, versus our expectation of -$0.56. A share count of... More
